Table 2.

Clinical trial program of JAKi in alopecia areata and subtypes according to clinicaltrials.gov.

Disease subtype	Inhibitor	Target	Administration	Phase	Study number
AA AU AT	Tofacitinib	JAK1 JAK3	Topical	Phase II	NCT02812342
	ATI-501	JAK1 JAK3	Oral	Phase II	NCT0359427
	ATI-502	JAK1 JAK3	Topical	Phase II	NCT03759340
AA AT	Ruxolitinib	JAK1 JAK2	Topical	Phase II	NCT02553330
	Baricitinib	JAK1 JAK2	Oral	Phase II/III	NCT03570749
	Tofacitinib	JAK1 JAK3	Oral	Phase IV	NCT03800979
	Tofacitinib	JAK1 JAK3	Oral	Phase II	NCT02299297
	Delgocitinib	PanJAK	Topical	Phase II	NCT02561585
	PF06651600	JAK3	Oral	Phase II	NCT02974868
	PF06700841	JAK1 TYK2
	PF-06651600	JAK3	Oral	Phase II	NCT03732807
	CTP-543	JAK1 JAK2	Oral	Phase II	NCT03811912
	CTP-543	JAK1 JAK2	Oral	Phase II	NCT03137381
eAA	Delgocitinib	PanJAK	Topical	Phase II	NCT03325296
	ATI-502	JAK1 JAK3	Topical	Phase II	NCT03551821

AA, alopecia areata; AU, alopecia universalis; AT, alopecia totalis; eAA, eyebrows alopecia areata.